BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Le Page C, Almadani N, Turashvili G, Bataillon G, Portelance L, Provencher D, Mes-Masson AM, Gilks B, Hoang L, Rahimi K. SATB2 Expression in Uterine Sarcoma: A Multicenter Retrospective Study. Int J Gynecol Pathol 2021;40:487-94. [PMID: 33720083 DOI: 10.1097/PGP.0000000000000730] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Szczepanski JM, Siddiqui J, Patel RM, Harms PW, Hrycaj SM, Chan MP. Expression of SATB2 in primary cutaneous sarcomatoid neoplasms: a potential diagnostic pitfall. Pathology 2023:S0031-3025(23)00002-8. [PMID: 36732203 DOI: 10.1016/j.pathol.2022.10.011] [Reference Citation Analysis]
2 Dyhdalo KS, Ababneh E, Lanigan C, Bowers K, Zhang S, McKenney JK, Joehlin-Price AS. Evaluation of Lineage/Site-specific Nuclear Immunohistochemical Markers SATB2, Cyclin D1, SALL4, and BCOR in High-grade Endometrial Carcinomas. Int J Gynecol Pathol 2022. [PMID: 36731037 DOI: 10.1097/PGP.0000000000000922] [Reference Citation Analysis]
3 Croce S, Devouassoux-Shisheboran M, Pautier P, Ray-Coquard I, Treilleux I, Neuville A, Arnould L, Just PA, Belda MALF, Averous G, Leroux A, Mery E, Loussouarn D, Weinbreck N, Le Guellec S, Mishellany F, Morice P, Guyon F, Genestie C. Uterine sarcomas and rare uterine mesenchymal tumors with malignant potential. Diagnostic guidelines of the French Sarcoma Group and the Rare Gynecological Tumors Group. Gynecol Oncol 2022:S0090-8258(22)00515-7. [PMID: 36114030 DOI: 10.1016/j.ygyno.2022.07.031] [Reference Citation Analysis]
4 Chapel DB, Nucci MR. An update in pathologic diagnosis of uterine mesenchymal tumours. Diagnostic Histopathology 2021;27:506-518. [DOI: 10.1016/j.mpdhp.2021.09.005] [Reference Citation Analysis]